The state of the art imaging test uses a molecule that binds to prostate cancer cells, causing them to “light up in a remarkable way”—appearing as bright spots in the scanning image. The process could safely halve the number of men who need to undergo a biopsy for suspected prostate cancer following inconclusive results from […]
by University of California, Los Angeles edited by Gaby Clark, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Credit: Marta Branco from Pexels A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men with prostate cancer,
by Jessica Saenz, Mayo Clinic edited by Lisa Lock, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Credit: Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.102638 Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically “cold,” meaning they do not attract enough immune cells to mount a strong attack. Hormone therapy commonly used
A potential immunotherapy strategy for early-stage prostate cancer Read More »
by Trinity College Dublin edited by Lisa Lock, reviewed by Alexander Pol Editors’ notes The GIST Add as preferred source Evolutionary double-bind therapy uses two therapies that explicitly target populations with different modes of therapy resistance. Credit: International Journal of Radiation Oncology*Biology*Physics (2026). DOI: 10.1016/j.ijrobp.2025.09.034 Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in
by Norwegian University of Science and Technology edited by Gaby Clark, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source This is what a frozen section of the prostate looks like. The researchers drilled small holes to extract tissue samples from areas where the gland contained cancer. It is precisely these tissue samples that were
New characteristics of aggressive prostate cancer identified Read More »
by National Comprehensive Cancer Network edited by Sadie Harley, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Credit: CC0 Public Domain New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment
New study unlocks important information about how to treat recurring prostate cancer Read More »
Not all cases of prostate cancer need followup and treatment, but determining which are serious and which are benign has been challenging. Peer-Reviewed Publication Norwegian University of Science and Technology image: Prostate cancer is the most common form of cancer among men in Western countries. The disease is naturally linked to aging. Professor Tone Frost
by Alliance for Clinical Trials in Oncology edited by Gaby Clark, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Credit: oscar Williams from Pexels A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes
Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment Read More »
edited by Sadie Harley, reviewed by Andrew Zinin Editors’ notes The GIST Add as preferred source Credit: Unsplash/CC0 Public Domain To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation Oncology developed the PSA Control Tower. This is
Predicting prostate cancer recurrence through power of AI Read More »
by American College of Physicians edited by Sadie Harley, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source Credit: Pixabay/CC0 Public Domain A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret prostate-specific antigen (PSA) test results compared to existing models. The tool, tested on
New model improves prediction of prostate cancer death risk Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866